İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2019 · article

Long-term follow-up results of patients with ADCK4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of CoQ10 supplementation

ISSN0041-4301
YÖKSİS OpenAlex Açık erişim · diamond TR Index
Yıl2019
Atıf21OpenAlex
Yüzdelik%70,8
FWCI0,771,00 = dünya ortalaması
Scopus (SJR)Q3
WoS (JCR)Q4

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıTURKISH JOURNAL OF PEDIATRICS
  • Katalog eşleşmesi (ISSN)Turkish Journal of Pediatrics
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

Atmaca M, Gülhan B, Atayar E, Karabay Bayazıt A, Candan C, Arıcı M, Topaloğlu R, Özaltın F. Long-term follow-up results of patients with ADCK4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of CoQ10 supplementation. Turk J Pediatr 2019; 61: 657-663. ADCK4-related glomerulopathy is a recently recognized clinical entity associated with insidious onset in young children and a high potential to progress to chronic kidney disease in adolescents. Early initiation of exogenous coenzyme Q10 (CoQ10) supplementation in the asymptomatic period could be protective on renal functions. In the present study, we aimed to investigate long-term follow-up of patients that we have diagnosed during the asymptomatic period and in whom we started CoQ10 treatment. We analyzed long-term effects of CoQ10 on proteinuria and estimated glomerular filtration rate (eGFR) in this patient population. A total of 8 patients (4 female, 4 male) from 6 different families were included. The mean age at diagnosis and at last visit were 16.8±11.2 years and 20.7±11.7 years, respectively. None of the patients had extrarenal system involvement. At the time of initiation of treatment; median eGFR was 107.8 ml/min/1.73 m2, median proteinuria was 1008 mg/m2/day. After a median follow-up period of 25.3±5.8 months, median proteinuria decreased to 318.5 mg/m2/day (p=0.03) and median eGFR remained stable at 99.6 ml/min/1.73 m2 (p=0.21). Coenzyme Q10 treatment is effective for reducing proteinuria and seems to be renoprotective.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

21atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 8 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2022 Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiencyAtıf 67 · OpenAlex
  2. 2022 Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiencyAtıf 67 · OpenAlex
  3. 2022 Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiencyAtıf 67 · OpenAlex
  4. 2022 Variation of the clinical spectrum and genotype-phenotype associations in Coenzyme Q10 deficiency associated glomerulopathyAtıf 48 · OpenAlex
  5. 2022 Variation of the clinical spectrum and genotype-phenotype associations in Coenzyme Q10 deficiency associated glomerulopathyAtıf 48 · OpenAlex
  6. 2022 Variation of the clinical spectrum and genotype-phenotype associations in Coenzyme Q10 deficiency associated glomerulopathyAtıf 48 · OpenAlex
  7. 2021 The Kidney in Mitochondrial DiseasesAtıf 1 · OpenAlex
  8. 2022 The Kidney in Mitochondrial DiseasesAtıf 0 · OpenAlex

Yazarlar

8
  1. MUSTAFA ATMACA 1
  2. BORA GÜLHAN HACETTEPE ÜNİVERSİTESİ 2
  3. EMİNE ATAYAR 3
  4. AYSUN KARABAY BAYAZIT 4
  5. CENGİZ CANDAN 5
  6. MUSTAFA ARICI 6
  7. REZAN TOPALOĞLU 7
  8. FATİH ÖZALTIN HACETTEPE ÜNİVERSİTESİ 8